2018 American Transplant Congress
Belatacept in Kidney Transplant Recipients with Preformed Donor Specific Anti-HLA Antibodies: Results of the BELACOR Trial
IntroductionAntibody-mediated rejection (ABMR) is currently a critical question in kidney transplant recipient with immunological risk factors such as pre transplant donor-specific anti HLA antibodies (DSA).…2018 American Transplant Congress
Identification of Anti-Inflammatory and Pro-Inflammatory Gut Microbiota That Determine Graft Survival
Introduction: The gut microbiota induce and train the host immune system. Whether microbiota from contrasting environments of colitic or pregnant mice are pro- or anti-inflammatory…2018 American Transplant Congress
Superior Renal Function with CNI-Free Everolimus over Standard CNI-Based Regimen: 18 Months Data from the Randomized, Multi-Center MANDELA Trial in De Novo Heart Transplant Recipients
1Mandela Study Group, Germany; 2Novartis, Pharma, Germany.
Purpose: The MANDELA study (NCT00862979) was designed to assess the benefit on renal function of either CNI-free or CNI-minimized EVR-based regimen after early conversion of…2018 American Transplant Congress
Association of Tacrolimus Adherence and Discontinuation with Sepsis Risk among Kidney Transplant Recipients
OBJECTIVE: The association between post-transplant tacrolimus exposure and sepsis risk is currently unknown. We examined the associations of tacrolimus adherence and discontinuation with sepsis risk…2018 American Transplant Congress
Human CD8+CD28– Ts Cells Expanded by Common Gamma Chain (γc) Cytokines Keep Steady Allospecific Suppressive Capacity In Vivo
Background: CD8+CD28- T suppressor (Ts) cells were recently reported to play a critical role in transplant tolerance, harnessing the potential for clinical use in transplantation.…2018 American Transplant Congress
Risk of Bacteremia According to Transplant Induction Immunosuppression Regimen
University of Wisconsin School of Medicine and Public Health, Madison.
Background: Transplant immune suppression is designed to suppress the adaptive immune response and ensure graft survival, but may have unintended effects on innate immunity. Few…2018 American Transplant Congress
Absence of Rejection in a Facial Allograft Recipient with a Postive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20+ Monoclonal Antibody
OBJECTIVE: Vascularized composite allograft (VCA) transplantation has become a feasible reconstructive option for patients with severe facial disfigurement. Short term patient and graft survival have…2018 American Transplant Congress
The Ratio of CTLA4 to Perforin and Granzyme B as a Potential Biomarker of Tolerance in Chimeric Renal Transplant Patients
Background: Thirty-six subjects have been enrolled in a phase II clinical trial aimed to induce tolerance through chimerism. Each subject received FCRx (mPBMC enriched in…2018 American Transplant Congress
Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients
Background: African American(AA) renal transplant recipients(RTR) require larger tacrolimus(TAC) doses to achieve similar troughs to Caucasians which may be due to CYP3A5 polymorphisms. TAC pharmacokinetics…2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…
- 1
- 2
- 3
- …
- 74
- Next Page »